Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?-Reference-Cited by-同舟云学术

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

Published:2020-01-03 Issue:4 Volume:22 Page:631-639
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Inzucchi Silvio E.¹,Fitchett David²,Jurišić‐Eržen Dubravka³,Woo Vincent⁴,Hantel Stefan⁵,Janista Christina⁵,Kaspers Stefan⁵,George Jyothis T.⁵,Zinman Bernard⁶,

Affiliation:

1. Section of Endocrinology Yale University School of Medicine New Haven Connecticut United States

2. St. Michael's Hospital, Division of Cardiology University of Toronto Toronto Ontario Canada

3. Department of Endocrinology and Diabetology, University Hospital Centre, Faculty of Medicine University of Rijeka Rijeka Croatia

4. Section of Endocrinology and Metabolism University of Manitoba Winnipeg Manitoba Canada

5. Boehringer Ingelheim International GmbH, Ingelheim Germany

6. Lunenfeld‐Tanenbaum Research Institute, Mount Sinai Hospital University of Toronto Toronto Ontario Canada

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13938

Reference40 articles.

1. Association of Cardiometabolic Multimorbidity With Mortality

2. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018

3. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes

4. Use of Antidiabetic Drugs in the U.S., 2003–2012

5. Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity;Scientific Reports;2024-09-05

2. ¿Ha cambiado el primer tratamiento de la diabetes mellitus tipo 2?;Medicina Clínica;2024-07

3. Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?;Frontiers in Endocrinology;2024-06-27

4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

5. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial;European Journal of Heart Failure;2024-05-15